BioSig Technologies says US Patent Office allows utility patent that its subsidiary NeuroClear had exclusively licensed from the Mayo Foundation

BioSig Technologies, Inc. (NASDAQ:BSGM), has said the US Patent Office has allowed a utility patent that its majority-owned subsidiary NeuroClear Technologies, Inc. had exclusively licensed from the Mayo Foundation for Medical Education and Research. The company said the recently allowed patent application number 16/805,017 entitled "Systems and Methods for Electroporation" was filed on February 28, 2020. The patent describes and claims methods and materials for improving the treatment of hypertension via electroporation of nerves in the renal area. Electroporation is an emerging technique that has demonstrated efficacy in treatments for several critical conditions and is currently being evaluated for the treatments of autonomic nervous disorders, including hyper and hypotension/syncope. READ: BioSig Technologies appoints Brenda Castrodad to lead its Human Resources department "We are pleased to announce this newest patent allowance which creates a patent foundation for the development of our N-SENSE platform technology. Our first neurostimulation product aims to address a vast market of neurological conditions through a proprietary sensing design and algorithms tailored to specific applications. Electroporation is a novel technique that has significantly advanced cancer treatments and has shown promise in treating cardiovascular disease. We look forward to exploring it further with our research partners,” commented Kenneth L. Londoner, chairman, and CEO of BioSig Technologies in a statement. The allowed patent application complements BioSig’s expanding patent portfolio, which now includes nine allowed/issued patents. Sixteen additional worldwide utility patent applications are pending covering various aspects of its PURE EP System for recording, measuring, calculating, and displaying of electrocardiograms during cardiac ablation procedures. The company has two additional pending US patent applications directed to artificial intelligence (AI).   The company has 24 allowed/issued worldwide design patents covering various features of its display screens and graphical user interface for enhanced visualization of biomedical signals. Finally, in addition to the patent referenced above, BioSig has exclusive licenses to 15 additional worldwide utility patent applications from Mayo Foundation for Medical Education and Research that are pending. These 15 applications are generally directed to electroporation and stimulation. BioSig is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals The company’s first product, PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring, and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. Contact the author at jon.hopkins@proactiveinvestors.com